Home > Insider Trading > Filing (0001293301-14-000007)

Filing Details

Accession Number:: 0001293301-14-000007
Form Type:: 4
Zero Holdings:: No
Publication Time:: 2014-01-27 16:52:18
Reporting Period:: 2014-01-24

Filing Date:: 2014-01-27
Accepted Time:: 2014-01-27 16:52:18
SEC Url:: Form 4 Filing

Issuer

Cik	Name	Symbol	Sector (SIC)	IRS No
38074	Forest Laboratories Inc	FRX	Pharmaceutical Preparations (2834)	111798614

Insiders

Cik	Name	Reported Address	Insider Title	Director	Officer	Large Shareholder	Other
1224339	Howard Solomon	C/O Forest Laboratories, Inc. 909 Third Avenue New York NY 10022		Yes	No	No	No

Reported Non-Derivative Transactions

Show Other Fields >>

Sec. Name	Acquisiton - Disposition	Date	Amount	Price	Remaning Holdings	Equity Swap Involved	Form Type	Code	Nature of Ownership
Common Stock	Disposition	2014-01-24	185,182	$65.27	529,699	No	4	S	Direct
Common Stock	Disposition	2014-01-24	37,527	$66.48	492,172	No	4	S	Direct
Common Stock	Disposition	2014-01-24	5,547	$67.05	486,625	No	4	S	Direct
Common Stock	Disposition	2014-01-27	21,744	$64.32	464,881	No	4	S	Direct

Equity Swap Involved	Form Type	Code	Nature of Ownership
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct
No	4	S	Direct

Footnotes

The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $65.00 to $65.90, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
This amount includes shares of common stock which are subject to a risk of forfeiture.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $66.01 to $66.97, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $67.00 to $67.23, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.
The price reported in Column 4 is a weighted average price. These shares were sold in multiple transactions at prices ranging from $64.03 to $64.67, inclusive. The Reporting Person undertakes to provide to the Company, any security holder of the Company, or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote.